Radiolabeled immunotherapy in non-hodgkin’s lymphoma treatment: the next step

Nuclear Medicine Communications

Volumn 30, Issue 1, 2009, Pages 5-15

  Otte, Andreas ^a   van de Wiele, Christophe ^a   Dierckx, Rudi A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

131I labeled tositumomab (Bexxar); 90Y ibritumomab tiuxetan (Zevalin); Chemotherapy; Non Hodgkin s lymphoma; Radiolabeled immunotherapy

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; ISOTOPE LABELING; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; REVIEW; VOMITING;

CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, NON-HODGKIN; MODELS, BIOLOGICAL; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 57749193774     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328313e565     Document Type: Review

References (84)

1. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:2453-2463.
2. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:3262-3269.
3. Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5:98-101.
4. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma. J Clin Oncol 2003; 21:1263-1270.
5. Emmanouilides C. Radioimmunotherapy for non-hodgkin lymphoma: historical perspective and current status. J Clin Exp Hematop 2007; 47:43-60.
6. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 10:54-58. Epub 2007 Mar 26.
7. Alousi AM, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, et al. Zevalin®/BEAM/Rituximab vs. BEAM/Rituximab and autologous stem cell transplantation (ASCT) for relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL): impact of the IPI and PET Status. Blood 2007; 110:abstract 620.
8. 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of relapsed or resistant aggressive diffuse large B-cell lymphoma (DLBCL) heavily pretreated with rituximab+chemotherapy: a GIMURELL experience. Blood 2007; 110:abstract 4478.
9. Venugopal P, Gregory SA, O’Brien T, Drasga R, Bayer R. Phase II study of 2-weekly CHOP+rituximab followed by yttrium 90 ibritumomab tiuxetan (Zevalin) in patients with previously untreated diffuse large B cell lymphoma (DLBCL). Blood 2007; 110:abstract 4507.
10. Hamlin PA, Moskowitz CH, Wegner BC, Portlock CS, Straus DJ, Noy A, et al. Early safety and efficacy analysis of a phase II study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (Zevalin®) for elderly high risk patients with untreated DLBCL. Blood 2005; 106:abstract 926.
11. Bertoni F, Ghielmini M, Cavalli F, Cotter FE, Zucca E. Mantle cell lymphoma: new treatments targeted to the biology. Clin Lymphoma 2002; 3:90-96.
12. 90Y-ibritumomab tiuxetan) radioimmunotherapy (RIT) consolidation in mantle cell lymphoma (MCL) patients, not illegible for intensive therapy protocols. Blood 2007; 110:abstract 4497.
13. 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499. Blood 2007; 110:abstract 389.
14. Weigert O, von Schilling C, Rummel MJ, Pezzutto A, Unterhalt M, Hiddemann W, Dreyling MH. Efficacy and safety of a single-course of yttrium-90 ibritumomab tiuxetan for treatment of patients with relapsed or refractory mantle cell lymphoma after/not appropriate for autologous stem cell transplantation - final analysis of a phase II trial of the European MCL Network. Blood 2007; 110:abstract 4501.
15. 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin’s lymphoma: a Children’s Oncology Group study. Clin Cancer Res 2007; 13 (18 Pt 2):5652s-5660s.
16. Chatterjee M, Chakraborty T, Tassone P. Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. Eur J Cancer 2006; 42:1640-1652.
17. Pitini V, Baldari S, Altavilla G, Arrigo C, Naro C, Perniciaro F. Salvage therapy for primary central nervous system lymphoma with (90)Y-ibritumomab and temozolomide. J Neurooncol 2007; 83:291-293; [Epub 2007 Jan 24].
18. Shah JJ, Meredith R, Shen S, Nabors B, Lobuglio A, Yester M, Forero A. Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy. Clin Lymphoma Myeloma 2006; 7:236-238.
19. Ferrucci PF, Vanazzi A, Tesoriere G, Ferrari M, Bartolomei M, Rocca P, et al. Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin’s lymphoma with central nervous system involvement. Ann Oncol 2005; 16:1710-1711; Epub 2005 Jun 21.
20. Schnell R, Dietlein M, Schomäcker K, Kobe C, Borchmann P, Schicha H, et al. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin’s lymphoma. Onkologie 2008; 31:49-51.
21. 90Y-ibritumomab tiuxetan in marginal-zone lymphoma (MZL). Blood 2007; 110:abstract 4499.
22. Tsimberidou AM, Murray JL, O’Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 2004; 100:2195-2200.
23. 90Y-ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin’s lymphoma: first results of the international randomized phase 3 First-Line Indolent Trial (FIT) in 414 Patients. Blood 2007; 110:abstract 643.
24. Kosters A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol 2005; 17:611-616.
25. Zini JM, Tobelem G. Angiogenesis and hematologic malignancy. Bull Cancer 2007; 94:S241-246.
26. Saito A, Takashima S, Takayama F, Kawakami S, Momose M, Matsushita T. Spontaneous extensive necrosis in non-Hodgkin lymphoma: prevalence and clinical significance. J Comput Assist Tomogr 2001; 25:482-486.
27. Mäntylä MJ. Regional blood flow in human tumors. Cancer Res 1979; 39:2304-2306.
28. Ochi A, Shibata S, Mori K. Ultrastructure of capillary permeability in malignant lymphoma. No Shinkei Geka 1989; 17:1139-1143.
29. Breen EC. VEGF in biological control. J Cell Biochem 2007; 15:1358-1367.
30. Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW, Madara K, Longo DL. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res 1993; 15:2204-2207.
31. Kadowaki I, Ichinohasama R, Harigae H, Ishizawa K, Okitsu Y, Kameoaka J, Sasaki T. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol 2005; 130:869-877.
32. Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene 2007; 26:3614-3628.
33. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin’s lymphoma. Clin Cancer Res 1999; 5 (10 Suppl):3292s-3303s.
34. 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 1999; 5 (10 Suppl):3287s-3291s.
35. 90Y-2IT-BAD-LYM-1 in patients with non-Hodgkin’s lymphoma. Anticancer Res 2000; 20:3647-3655.
36. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin’s lymphoma. Clin Cancer Res 1999; 5 (10 Suppl):3330s-3336s.
37. 67Cu-2IT-BAT-Lym-1 for non-Hodgkin’s lymphoma. J Nucl Med 1999; 40:2014-2020.
38. 211At-rituximab against non-Hodgkin’s lymphoma cells. Br J Cancer 2000; 83:1375-1379.
39. 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 2002; 16:60-66.
40. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol 1998; 16:3246-3256.
41. 186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma [letter]. Blood 2004; 103:1175.
42. Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland OS, et al. Targeted cancer therapy with a novel low dose rate alpha-emitting radioimmunoconjugate. Blood 2007; 110:2049-2056. [Epub 2007 May 29].
43. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-4342.
44. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109:1804-1810.
45. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 2008; 19:769-773. [Epub 2008 Feb 25].
46. 90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant 2007; 40:1007-1017. Epub 2007 Oct 8; advance online publication, 8 October 2007; doi:10.1038/sj.bmt.1705868.
47. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin’s lymphoma. Exp Hematol 2007; 35:534-540.
48. Bethge WA, Thoralf L, Bornhaeuser M, Stadler M, Uharek L, Knop S, et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: a phase I/II study. Blood 2007; 110:abstract 3059.
49. Gisselbrecht C, Decaudin D, Mounier N, Tilly H, Ribrag V, Sebban C, et al. 90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. GELA Phase II Study. Blood 2007; 110:abstract 22.
50. 90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHSCT) for poor-risk or refractory B-cell non-Hodgkin’s lymphoma. Blood 2007; 110:abstract 1891.
51. 90Y-ibritumomab tiuxetan with high-dose chemotherapy (Busulfan/Cyclophosphamide/Etoposide) followed by autologous stem cell transplantation in relapsed, refractoried, or high-risk B-cell NHL. Blood 2007; 110:abstract 1914.
52. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [(18)F]FLT. Eur J Nucl Med Mol Imaging 2007; 34:1775-1782. [Epub 2007 May 31].
53. Schomacker K, Dietlein M, Schnell R, Pinkert J, Eschner W, Zimmermanns B, et al. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives (article in German). Nuklearmedizin 2005; 44:166-177.
54. Zimmer AM. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 2004; 34 (Suppl 1):14-19.
55. Meredith RF. Logistics of therapy with the ibritumomab tiuxetan regimen. Int J Radiat Oncol Biol Phys 2006; 66 (2 Suppl):S35-S38.
56. Eschner W, Breustedt B, Lassmann M, Hänscheid H. Erfassung der über Ausscheidungen in die Umwelt abgegebenen radioaktiven Stoffe nach ihrer Anwendung in der Nuklearmedizin. Schriftenreihe Reaktorsicherheit und Strahlenschutz, Bundesministerium für Umwelt, Naturschutz und Reaktorsicherheit. BMU 2004; 649.
57. 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin’s lymphoma. J Nucl Med 2001; 42:286P. (suppl; abstract).
58. Verordnung über den Schutz vor Schäden durch ionisierende Strahlen: StrSchV Strahlenschutzverordnung, BGBl. I Nr. 38 vom 26.07.2001, Anlage VII Tabelle 4.
59. Strahlenschutzkommission. Radioimmuntherapie mit Y-90-Ibritumomab-Tiuxetan (Y-90-Zevalin), Empfehlung der Strahlenschutzkommission, 198. Sitzung, 17.02.2005.
60. Geworski L, Zophel K, Rimpler A, Barth I, Lassmann M, Sandrock D, et al. Radiation exposure in (90)Y-Zevalin therapy: results of a prospective multicentre trial (article in German). Nuklearmedizin 2006; 45:82-86. quiz N15-6.
61. Hendrix C. Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy. Semin Oncol Nurs 2004; 20 (Suppl 1):14-19.
62. Zhu X. Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 2004; 34 (Suppl 1):20-23.
63. Zhu X. Radiation safety considerations with therapeutic 90Y Zevalin. Health Phys 2003; 85 (2 Suppl):S31-S35.
64. Otte A, Dierckx RA. Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin’s lymphoma: is there an increased risk? Nucl Med Commun 2005; 26:1045-1047.
65. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007; 25:4285-4292. Epub 2007 Aug 20.
66. Krishnan AY, Palmer JM, Bhatia SC, Nademanee A, Forman SJ, Raubitschek A, et al. The Impact of incorporating targeted radioimmunotherapy (RIT) into transplant preparative regimens on the incidence of therapy related myelodysplasia (t-MDS) or AML (t-AML) following autologous stem cell transplant (ASCT) for lymphoma. Blood 2007; 110:abstract 1082.
67. Gordon LI. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Oncol 2003; 30 (6 Suppl 17):23-28.
68. Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005; 16:786-792. Epub 2005 Mar 31.
69. Conti PS. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician. Semin Nucl Med 2004; 34 (1 Suppl 1):2-3.
70. Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med 2005l; 46:1812-1818.
71. 90Y-ibritumomab tiuxetan (Zevalin®) treatment in follicular non-Hodgkin’s lymphoma. Hell J Nucl Med 2008; 11:12-15.
72. Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2003; 44:853.
73. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44:465-474. Comment in: J Nucl Med 2003 44(10):1707-1708. J Nucl Med 2004; 45:924-925.
74. 90Y-ibritumomab tiuxetan (Zevalin®) given as consolidation of first remission in patients with advanced-stage follicular lymphoma in the international phase 3 First-Line Indolent Trial (FIT). Blood 2007; 110:abstract 3415.
75. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 2001; 39:181-194.
76. Berenson A. Market forces cited in lymphoma drugs’ disuse. New York Times 2007.
77. Gabriel A, Hänel M, Wehmeyer J, Griesinger F. Advantages in cost effectiveness of Zevalin® radioimmunotherapy vs. rituximab immunotherapy in patients with relapsed or refractory follicular non-Hodgkin’s lymphoma. Onkologie 2005; 28 (Suppl 3):236. [abstract].
78. 90Y-Zevalin) versus rituximab monotherapy in patients with relapsed follicular lymphoma. Blood 2005; 106:436. [abstract].
79. Van Agthoven M, Uyl-de Groot CA, Sonneveld P, Hagenbeek A. Economic assessment in the management of non-Hodgkin’s lymphoma. Expert Opin Pharmacother 2004; 5:2529-2548.
80. Sweetenham J, Hieke K, Kerrigan M, Howard P, Smartt PF, McIntyre AM, et al. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s lymphoma in U.K. Br J Haematol 1999; 106:47-54.
81. Herold M, Sacchi S, Hieke K. The cost of treating relapsed indolent non-Hodgkin’s lymphoma in an international setting: retrospective analysis of resource use. Haematologica 2002; 87:719-729. [discussion 729].
82. Van Agthoven M, Kramer MHH, Sonneveld P, Van der Hem KG, Huijgens PC, Wijermans PW, et al. Cost analysis of common treatment options for indolent follicular non-Hodgkin’s lymphoma. Haematologica 2005; 90:1422-1432.
83. 90Y-ibritumomab tiuxetan radioimmunotherapy versus cost of standard regimens for the treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma in Switzerland. Blood 2007; 110:abstract 3320.
84. 90Y-ibritumomab tiuxetan (Zevalin®) of first remission: results from the randomized phase 3 First-Line Indolent Trial (FIT). Blood 2007; 110:abstract 3319.